Takimoto, Chris H <br/><br/>
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jul 2003 
 - 2664-72 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2003.11.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Glomerular Filtration Rate--drug effects<br/>Humans<br/>Infusions, Intravenous<br/>Kidney Diseases--physiopathology<br/>Kidney Function Tests<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>National Institutes of Health (U.S.)<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Probability<br/>Reference Values<br/>Risk Assessment<br/>Severity of Illness Index<br/>Survival Analysis<br/>Treatment Outcome<br/>United States